Keyphrases
Activated Cells
100%
Interleukin-2
100%
Minimal Residual Disease
100%
Malignant Disorders
100%
Cellular Immunotherapy
100%
Allogeneic Lymphocytes
100%
BCL1
66%
Allogeneic
44%
Spleen Cells
44%
Graft-versus-leukemia Effect
33%
Cetus
33%
Allogeneic BMT
33%
High Dose
22%
Leukemia
22%
Allograft
22%
T Cell Depletion
22%
Autologous BMT
22%
T Cells
11%
Disease States
11%
Bone Marrow
11%
Lymphocytes
11%
Consecutive Days
11%
Reconstitution
11%
Leukemia Cells
11%
Balb C Mice
11%
Cyclophosphamide
11%
Therapeutic Tool
11%
Therapeutic Benefits
11%
Disease-free
11%
Antitumor Effect
11%
Human interleukin-2
11%
Syngeneic
11%
Marrow
11%
Tumor Model
11%
Non-immunogenic
11%
Ther
11%
B-cell Leukemia
11%
Anti-leukemia
11%
No Evidence of Disease
11%
Leukemic Relapse
11%
Medicine and Dentistry
Immunotherapy
100%
Interleukin 2
100%
Minimal Residual Disease
100%
Disease
100%
Lymphocyte
100%
Spleen Cell
40%
Graft Versus Leukemia Effect
30%
T Cell
20%
Leukemia
20%
Allograft
20%
Drug Megadose
20%
Diseases
20%
Neoplasm
10%
Low Drug Dose
10%
Cyclophosphamide
10%
Graft Versus Host Reaction
10%
Leukemia Cell
10%
T Lymphocyte
10%
Tumor Model
10%
B Cell Leukemia
10%
Veterinary Science and Veterinary Medicine
Lymphocyte
100%
Leukemia
100%
Diseases
100%
Mouse
85%
Splenocyte
57%
T Cell
42%
BALB/c
28%
Neoplasm
28%
B Cell
14%
Immunology and Microbiology
Immunotherapy
100%
Interleukin 2
100%
Lymphocyte
100%
Splenocyte
40%
T Cell
30%
Drug Megadose
20%
Allograft
20%
B Cell
10%
Leukemia Cell
10%
Bagg Albino Mouse
10%
Low Drug Dose
10%
Experimental Model
10%
Cyclophosphamide
10%
Syngenic
10%
Graft-Versus-Host Disease
10%